Schistosome immunology: More questions than answers

Parasitology Today

Volumn 14, Issue 10, 1998, Pages 407-412

  Hagan, P ^c   Ndhlovu, P D ^a   Dunne, D W ^b  

^a Blair Research Institute   (Zimbabwe)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN E; INTERLEUKIN 4; INTERLEUKIN 5; MOLLUSCACIDE; PRAZIQUANTEL; SCHISTOSOMA VACCINE;

AGE; DISEASE RESISTANCE; DISEASE TRANSMISSION; EOSINOPHIL; HELPER CELL; HEREDITY; HUMAN; IMMUNE RESPONSE; NONHUMAN; REVIEW; SCHISTOSOMIASIS;

EID: 0031772141     PISSN: 01694758     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-4758(98)01325-8     Document Type: Review

References (59)

1. Butterworth A.E.et al. Immunity after treatment of human schistosomiasis mansoni. II. Identification of resistant individuals and analysis of their immune responses. Trans. R. Soc. Trop. Med. Hyg. 79:1985;393-408.
2. Wilkins H.A.et al. Resistance to reinfection after treatment of urinary schistosomiasis. Trans. R. Soc. Trop. Med. Hyg. 81:1987;29-35.
3. Butterworth, A.E. (1993) in Human Schistosomiasis (Jordan, P., Webbe, G. and Sturrock R.F., eds), pp 331-366, CAB International.
4. Medhat, A. et al. Increased IL-4 and IL-5 production correlates with protective immunity to urinary schistosomiasis. J. Infect. Dis. (in press).
5. Roberts M.et al. Immunity after treatment of human schistosomiasis: association between cellular responses and resistance to reinfection. Infect. Immun. 61:1993;4984-4993.
6. Hagan P.et al. Human IgE, IgG4 and resistance to reinfection with Schistosoma haematobium. Nature. 349:1991;243-245.
7. Rihet P.et al. Evidence for an association between human resistance to Schistosoma mansoni and high anti-larval IgE levels. Eur. J. Immunol. 21:1991;2679-2686.
8. Dunne D.W.et al. Immunity after treatment of schistosomiasis: association between IgE antibodies to adult worm antigens and resistance to reinfection. Eur J. Immunol. 22:1992;1483-1494.
9. Hagan P.et al. Eosinophilia and resistance to Schistosoma haematobium in man. Parasite Immunol. 7:1985;617-624.
10. Abel L.et al. Evidence for the segregation of a major gene in human susceptibility/resistance to infection by Schistosoma mansoni. Am. J. Hum. Gen. 48:1991;959-970.
11. Marquet S.et al. Genetic localization of a locus controlling the intensity of infection by Schistosoma mansoni on chromosome 5q31-q33. Nat. Genet. 14:1996;181-184.
12. Ongom V.L., Bradley D.J. The epidemiology and consequences of Schistosoma mansoni infection in West Nile, Uganda. I. Field studies of a community at Panyagoro. Trans. R. Soc. Trop. Med. Hyg. 66:1972;835-851.
13. Forsyth D.M., Bradley D.J. The consequences of bilharziasis. Medical and public health importance in north-west Tanzania. Bull. WHO. 34:1966;715-735.
14. Jordan, P. and Webbe, G. (1993) in Human Schistosomiasis (Jordan, P., Webbe, G. and Sturrock R.F., eds), pp 87-158, CAB International.
15. Butterworth A.E. Human immunity to schistosomes - some questions. Parasitol. Today. 10:1994;378-380.
16. Woolhouse M.E.et al. Acquired immunity and epidemiology of Schistosoma haematobium. Nature. 351:1991;757-759.
17. Fulford A.J.C.et al. On the use of age-intensity data to detect immunity to parasitic infections, with special reference to Schistosoma mansoni in Kenya. Parasitology. 105:1992;219-227.
18. Fulford A.J.C.et al. Puberty and age-related changes in susceptibility to schistosome infection. Parasitol. Today. 14:1998;23-26.
19. Talla I.et al. Outbreak of intestinal schistosomiasis in the Senegal River Basin. Ann. Soc. Belge Med. Trop. 70:1990;173-180.
20. Stelma F.F.et al. Epidemiology of Schistosoma mansoni infection in a recently exposed community in northern Senegal. Am. J. Trop. Med. Hyg. 49:1993;701-706.
21. Davis, A. (1993) in Human Schistosomiasis (Jordan, P., Webbe, G. and Sturrock R.F., eds), pp 367-404, CAB International.
22. Fallon P.G.et al. Short report: diminished susceptibility to praziquantel in a Senegal isolate of Schistosoma mansoni. Am. J. Trop. Med. Hyg. 53:1995;61-62.
23. Stelma F.F.et al. Efficacy and side-effects of praziquantel in an epidemic focus of Schistosoma mansoni. Am. J. Trop. Med. Hyg. 53:1995;167-170.
24. Ismael M.et al. Characterization of isolates of Schistosoma mansoni from Egyptian villagers that tolerate high doses of praziquantel. Am. J. Trop. Med. Hyg. 55:1996;214-218.
25. Picquet M.et al. Efficacy of praziquantel against Schistosoma mansoni in northern Senegal. Trans. R. Soc. Trop. Med. Hyg. 92:1998;90-93.
26. WHO (1993) The Control of Schistosomiasis. Second Report of the WHO Expert Committee Tech. Rep. Ser. 830.
27. Wilson R.A., Coulson P.S. Why don't we have a schistosomiasis vaccine? Parasitol. Today. 14:1998;97-99.
28. Bergquist R., Colley D.G. Schistosomiasis vaccines: research to development. Parasitol. Today. 14:1998;99-104.
29. Wilkins H.A.et al. Dynamics of Schistosoma haematobium infection in a Gambian community. I. The pattern of human infection in the study area. Trans. R. Soc. Trop. Med. Hyg. 78:1984;216-221.
30. Wilkins H.A.et al. Dynamics of Schistosoma haematobium infection in a Gambian community. III. Acquisition and loss of infection. Trans. R. Soc. Trop. Med. Hyg. 78:1984;227-232.
31. Butterworth A.E., Hagan P. Immunity in human schistosomiasis. Parasitol. Today. 3:1987;11-16.
32. Bundy, D.A.P. and Blumenthal, U.J. (1990) in Parasitism and Human Behaviour (Barnard, C.J. and Behnke, J.M., eds), pp 264-289, Taylor & Francis.
33. Fulford A.J.C.et al. Water contact observations in Kenyan communities endemic for schistosomiasis: methodology and patterns of behaviour. Parasitology. 113:1996;223-241.
34. Gryseels B. Human resistance to Schistosoma mansoni infections - age or experience. Parasitol. Today. 10:1994;380-384.
35. Woolhouse M.E.J. Immunoepidemiology of human schistosomes - taking the theory into the field. Parasitol. Today. 10:1994;196-202.
36. Ouma J.H.et al. The development of schistosomiasis mansoni in an immunologically naive immigrant population in Masongaleni, Kenya. Parasitology. 117:1998;123-132.
37. Woolhouse M.E.J. Mathematical models of transmission dynamics and control of schistosomiasis. Am. J. Trop. Med. Hyg. 55:1996;144-148.
38. Michael E., Bundy D.A.P. Herd immunity to filarial infection is a function of vector biting rate. Proc. R. Soc. London Ser. B. 265:1998;855-860.
39. Butterworth A.E.et al. Antibody-dependent cell-mediated damage to schistosomula in vitro. Nature. 252:1974;503-505.
40. Butterworth A.E.et al. Eosinophils as mediators of antibody-dependent damage to schistosomula. Nature. 256:1975;727-729.
41. Caulada-Benedetti Z.et al. Comparison of Th1 and Th2 associated immune reactivities stimulated by single versus multiple vaccination of mice with irradiated Schistosoma mansoni cercariae. J. Immunol. 146:1991;1655-1660.
42. Vignali D.A.A., Bickle Q.D., Taylor M.G. Immunity to Schistosoma mansoni in vivo - contradiction or clarification. Immunol. Today. 10:1989;410-416.
43. Couissinier-Paris P., Dessein A.J. Schistosoma-specific helper T cell clones from subjects resistant to infection by Schistosoma mansoni are Th0/2. Eur. J. Immunol. 25:1995;2295-2302.
44. Pearce E.J.et al. Downregulation of Th1 cytokine production accompanies induction of Th2 responses by a parasitic helminth, Schistosoma mansoni. J. Exp. Med. 173:1991;159-166.
45. Mosmann T.R.et al. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol. 136:1986;2348-2357.
46. Allen J.E., Maizels R.M. Th1-Th2: reliable paradigm or dangerous dogma? Immunol. Today. 18:1997;387-392.
47. Wilson R.A. Leaky livers, portal shunting and immunity to schistosomes. Parasitol. Today. 6:1990;354-358.
48. Lambertucci, J.R. (1993) in Human Schistosomiasis (Jordan, P., Webbe, G. and Sturrock R.F., eds), pp 195-235, CAB International.
49. Chen, M.G. (1993) in Human Schistosomiasis (Jordan, P., Webbe, G. and Sturrock R.F., eds), pp 237-270, CAB International.
50. Mwatha J.K.et al. High levels of TNF, soluble TNF receptors, sICAM-1 and IFN-gamma, but low levels of IL-5, are associated with hepatosplenic disease in human schistosomiasis mansoni. J. Immunol. 160:1998;1992-1999.
51. WHO (1974) Immunology of schistosomiasis. Bull. WHO 51, 553-595.
52. Grogan J.L.et al. Anti-schistosome IgG4 and IgE responses are affected differentially by chemotherapy in children versus adults. J. Infect. Dis. 173:1996;1242-1247.
53. Grogan J.L.et al. Anti-schistosome IgG4 and IgE at 2 years after chemotherapy: infected versus uninfected individuals. J. Infect. Dis. 176:1997;1344-1350.
54. Mutapi F.et al. Chemotherapy accelerates the development of acquired immune responses to Schistosoma haematobium infection. J. Infect. Dis. 178:1998;289-293.
55. Webster M.et al. Effect of praziquantel and oxamniquine treatment on human isotype responses to Schistosoma mansoni: elevated IgE to adult worm. Parasite Immunol. 19:1997;333-335.
56. Webster M.et al. IgG4 and IgE responses to Schistosoma mansoni adult worms after treatment. J. Infect. Dis. 175:1997;493-494.
57. Agnew A.et al. Age-dependent reduction of schistosome fecundity in Schistosoma haematobium but not Schistosoma mansoni infections in humans. Am. J. Trop. Med. Hyg. 55:1996;338-343.
58. Woolhouse M.E.J. Human schistosomiasis: potential consequences of vaccination. Vaccine. 13:1995;1045-1050.
59. Wilkins H.A.et al. The significance of proteinuria and haematuria in Schistosoma haematobium infection. Trans. R. Soc. Trop. Med. Hyg. 73:1979;74-80.